Clinical trials: Adaptive Immunity
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus (RSV), Respiratory Infection Virus
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in…
- Trial name
- THRIVE (NCT07578298)
- Testing
- Nirsevimab (RSV-specific monoclonal antibody)
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
- Trial name
- NCT03028974
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Stanford University
Malaria
Age of Exposure and Immunity to Malaria in Infants
The overall objective is to evaluate the effect of exposure to Plasmodium (P.) falciparum erythrocytic stage antigens during different periods of infancy on the development of naturally acquired immunity (NAI).
- Trial name
- NCT00231452
- Testing
- Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
- Where
- Mozambique
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Malaria
Correlates of Protection in Ghana
Malaria is a sickness passed from one person to the other by the bite of a mosquito. In areas of frequent malaria infection, children may develop natural protection against malaria and they are less likely to become sick or die…
- Trial name
- NCT00138307
- Where
- 2 sites in Ghana
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Healthy
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed influenza vaccines in children.
- Trial name
- SLVP030 (NCT03453801)
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Stanford University
Childhood Pneumonia, Mycoplasma Pneumonia
Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)
To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and…
- Conditions
- Childhood Pneumonia, Mycoplasma Pneumonia, Antibody-secreting Cells, Enzyme-linked Immunospot (ELISpot)
- Trial name
- myCAP (NCT03613636)
- Testing
- Enzyme-linked immunospot (ELISpot) assay [Blood]
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Malaria, Falciparum
Malaria Transmission Studies in Mali
Background: Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person.
- Trial name
- NCT01829737
- Where
- United States
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)